John T. Cavan, Chief Financial Officer at Hepion Pharmaceuticals, Inc. (HEPA), bought 4,500 shares at $1.62 ($7K) on 2020-11-25, disclosed to the SEC on 2020-11-30.
Open-market purchase of $7k HEPA by Chief Financial Officer. Below the thresholds we flag for high-conviction alerts (no C-suite role, rare reversal, cluster, or A-grade history). Context: insider career grade D.
Clearly above the average filing.
| Filing → |